Literature DB >> 9094843

Primary care paradigm for management of sarcoidosis, Part 1.

R C Young1, R E Rachal, B Nelson-Knuckles, C N Arthur, H V Nevels.   

Abstract

Sarcoidosis is a systemic granulomatous disease of undetermined etiology in which the immune system is overstimulated. Management of the patient with sarcoidosis entails continuity of patient care far beyond disease, even into remission. Care is comprehensive, including all involved organ systems, coordination of specialty consultations and services, and diagnostic tests. Therapeutic decisions are the responsibility of the primary care practitioner. Prognosis of sarcoidosis is not uniformly good. Patients can die. Subacute sarcoidosis patients usually do not require pharmacologic therapy. Chronic sarcoidosis may require long-term treatment for years to indefinitely. Corticosteroids are still the drugs of choice and other therapy is now available. Health organizations and private nonprofit support groups are available for patient education and assistance. Close support must still come from the family unit. Sarcoidosis may occur in family members in different cohorts at all ages in life and in any racial or ethnic group. This article is the first in a two-part series on management of the patient with sarcoidosis in the 21 st century by the primary are provider. Applications of principles of family medicine are emphasized. Part 1 considers continuity, comprehensiveness, and coordination of care. Part 2 will complete coordination of care, and consider community, prevention, and family aspects of this disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9094843      PMCID: PMC2608241     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  30 in total

1.  The treatment of sarcoidosis with chloroquine.

Authors:  S I MORSE; Z A COHN; J G HIRSCH; R W SCHAEDER
Journal:  Am J Med       Date:  1961-05       Impact factor: 4.965

2.  The MOS short-form general health survey. Reliability and validity in a patient population.

Authors:  A L Stewart; R D Hays; J E Ware
Journal:  Med Care       Date:  1988-07       Impact factor: 2.983

3.  A controlled trial of prednisone treatment of sarcoidosis.

Authors:  H L Israel; D W Fouts; R A Beggs
Journal:  Am Rev Respir Dis       Date:  1973-04

4.  A long-term study of sarcoid and its modification by steroid therapy. Lung function and other factors in prognosis.

Authors:  D J Stone; A Schwartz
Journal:  Am J Med       Date:  1966-10       Impact factor: 4.965

5.  The surgical aspects of sarcoidosis. With particular reference to some apparent cures following surgical procedures.

Authors:  C R Lam
Journal:  Arch Surg       Date:  1968-09

6.  Sarcoidosis in Washington, D. C. Clinical observations in 105 black patients.

Authors:  R C Young; P Y Titus-Dillon; M L Schneider; T G Shelton; R L Hackney; K A Harden
Journal:  Arch Intern Med       Date:  1970-01

7.  Pulmonary sarcoidosis: a prospective evaluation of glucocorticoid therapy.

Authors:  R L Young; L E Harkleroad; R E Lordon; J G Weg
Journal:  Ann Intern Med       Date:  1970-08       Impact factor: 25.391

8.  Methotrexate for chronic diseases in adults.

Authors:  M E Weinblatt
Journal:  N Engl J Med       Date:  1995-02-02       Impact factor: 91.245

9.  Use of budesonide in the treatment of pulmonary sarcoidosis.

Authors:  O B Selroos
Journal:  Ann N Y Acad Sci       Date:  1986       Impact factor: 5.691

10.  When should sarcoidosis be treated?

Authors:  R C Young; R E Rachal; C L Cowan
Journal:  J Natl Med Assoc       Date:  1986-09       Impact factor: 1.798

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.